GUIDED THERAPEUTICS INC Form 8-K October 08, 2009

#### SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

### FORM 8-K

### **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): October 8, 2009 (October 5, 2009)

### GUIDED THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware 0-22179 58-2029543
(State or Other Jurisdiction (Commission File of Incorporation) Number) Identification No.)

4955 Avalon Ridge Pkwy, Suite 300

Norcross, Georgia

30071

(Zip Code)

(Address of Principal Executive Offices)

Registrant's Telephone Number, Including Area Code: (770) 242-8723

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions :

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

On October 5, 2009, Guided Therapeutics, Inc. reported that it was awarded a \$2.5 million matching grant by the National Cancer Institute, as more fully described in the press release, a copy of which is furnished as Exhibit 99.1 hereto and which information is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

The following exhibits are filed with this report:

Exhibit No. Exhibit Description

99.1 Press Release, dated October 5, 2009

- 2 -

### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

By:

**GUIDED** 

THERAPEUTICS,

**INC** 

/s/ MARK L. FAUPEL

Mark L. Faupel,

Ph.D.

CEO & President

Date: October 8, 2009

- 3 -